Skip to content

Study · Animal study (in vivo) · mouse · 2021

2 results

Follicle-stimulating hormone promotes growth of human prostate cancer cell line-derived tumor xenografts.

Oduwole OO, Poliandri A, Okolo A, Rawson P, Doroszko M, Chrusciel M, Rahman NA, Serrano de Almeida G, Bevan CL, Koechling W, Huhtaniemi IT

FASEB journal : official publication of the Federation of American Societies for Experimental Biology1 Apr 2021Cited by 14 (Europe PMC)

PMID33724574 (opens in a new tab)DOI10.1096/fj.202002168rr (opens in a new tab)PepBankPUB-33724574
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In nude mice bearing PC-3 xenografts, degarelix suppressed tumor growth.

    In plain wordsIn mice bearing PC-3 tumors, degarelix suppressed tumor growth.

    Peptide
    Degarelix
    Outcome
    DecreasePC-3 tumor growth
    Study

    mousen: not reported in source

    Human prostate cancer xenografts in nude mice
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All tumors expressed GnRHR and FSHR, and degarelix treatment suppressed their growth.
    3 context sentences
    Summary · context
    FSH supplementation reversed the degarelix-evoked suppression of PC-3 tumors, both in preventive (degarelix and FSH treatment started upon cell inoculation) and therapeutic (treatments initiated 3 weeks after cell inoculation) setting.
    Summary · context
    We herein assessed the role of FSH in promoting the growth of androgen-independent (PC-3, DU145) and androgen-dependent (VCaP) human prostate cancer cell line xenografts in nude mice.
    Summary · context
    Gonadotropins were suppressed with the GnRH antagonist degarelix, and effects of add-back human recombinant FSH were assessed on tumor growth.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In nude mice bearing DU145 xenografts, degarelix suppressed tumor growth.

    In plain wordsIn mice bearing DU145 tumors, degarelix suppressed tumor growth.

    Peptide
    Degarelix
    Outcome
    DecreaseDU145 tumor growth
    Study

    mousen: not reported in source

    Human prostate cancer xenografts in nude mice
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All tumors expressed GnRHR and FSHR, and degarelix treatment suppressed their growth.
    2 context sentences
    Summary · context
    We herein assessed the role of FSH in promoting the growth of androgen-independent (PC-3, DU145) and androgen-dependent (VCaP) human prostate cancer cell line xenografts in nude mice.
    Summary · context
    Gonadotropins were suppressed with the GnRH antagonist degarelix, and effects of add-back human recombinant FSH were assessed on tumor growth.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.